GLYC GlycoMimetics
- 0.3826
- -0.0243-5.97%
- 0.3610
- -0.0216-5.65%
GlycoMimetics News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)
GlycoMimetics Analyst Ratings
TD Cowen Downgrades GlycoMimetics(GLYC.US) to Hold Rating
GlycoMimetics (GLYC) Was Downgraded to a Hold Rating at TD Cowen
Capital One Financial Maintains GlycoMimetics(GLYC.US) With Hold Rating, Maintains Target Price $0.5
GlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold Rating
H.C. Wainwright Maintains GlycoMimetics(GLYC.US) With Hold Rating
H.C. Wainwright Remains a Hold on GlycoMimetics (GLYC)
GlycoMimetics Analyst Ratings
Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50
GlycoMimetics' Uproleselan: Hold Rating Amidst Strategic Reevaluation and Uncertain Future
GlycoMimetics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: GlycoMimetics (GLYC) and Gossamer Bio (GOSS)
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)
Positive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth Initiatives
GlycoMimetics Analyst Ratings
Buy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of Uproleselan
Promising Outlook for GlycoMimetics' Uproleselan in AML Treatment: A Buy Rating With Adjusted Price Target
Buy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for Uproleselan
Capital One Initiates Coverage On GlycoMimetics With Overweight Rating, Announces Price Target of $12
Analysis
Price Target
No Data
No Data